Literature DB >> 8057214

Endomysial antibody screening in children.

K N Chan1, A D Phillips, R Mirakian, J A Walker-Smith.   

Abstract

It has been suggested that endomysial antibodies are specific markers for coeliac disease. In a 13-month study, we examined the usefulness of screening for these antibodies in the diagnosis of coeliac disease in children. Twenty-one of 223 (9.4%) serum samples [or 17 of 192 (9%) children undergoing investigation for GI disorders] were found to be positive for serum IgA class endomysial antibodies. These included eight strong positives, eight positives, and five weak positives. One-hundred-thirty-four children had small bowel biopsies performed. Endomysial antibodies were found in all children with severe villous atrophy on a gluten-containing diet who were diagnosed as having coeliac disease. Three children with positive and four with weak-positive results did not have coeliac disease. One had partial villous atrophy consistent with the diagnosis of cow-milk-sensitive enteropathy and the others had a normal small bowel mucosa. This study confirms a strong association between endomysial antibodies and coeliac disease; however, not all cases with positive antibodies had the disease. At the present time, small bowel biopsy remains essential for the diagnosis of coeliac disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8057214     DOI: 10.1097/00005176-199404000-00011

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  2 in total

1.  Serologic testing for celiac disease in the United States: results of a multilaboratory comparison study.

Authors:  J A Murray; J Herlein; F Mitros; J A Goeken
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

2.  Clinical application of immunological markers as monitoring tests in celiac disease.

Authors:  M Fotoulaki; S Nousia-Arvanitakis; P Augoustidou-Savvopoulou; F Kanakoudi-Tsakalides; T Zaramboukas; J Vlachonikolis
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.